Clinical Trials Browser

exemestane × 30 days × Clear all

NCT06179303 2026-04-16

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Recruiting

Anatomic Stage III Breast Cancer AJCC v8

NCT07062965 2026-04-16

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT04852887 2026-04-15

DEBRA

Phase 3 Recruiting

Breast Neoplasms

NCT01127295 2026-04-14

PHACS

Phase 4 Completed

Breast Neoplasms

NCT01553903 2026-04-14

OXYTAM

Phase 4 Completed

Breast Neoplasms

NCT01612871 2026-04-14

MIRHO

Phase 4 Completed

Breast Neoplasms

NCT05827081 2026-04-14

Adjuvant WIDER

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT06380751 2026-04-14

EvoPAR-BR01

Phase 3 Recruiting

Advanced Breast Cancer

NCT00310180 2026-04-13

TAILORx

Phase 3 Active not recruiting

10,273 enrolled 14 charts

Breast Neoplasms

NCT01272037 2026-04-13

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Phase 3 Active not recruiting

5,018 enrolled 14 charts

Carcinoma, Intraductal, Noninfiltrating

NCT05774951 2026-04-13

CAMBRIA-1

Phase 3 Recruiting

Breast Neoplasms

NCT06169124 2026-04-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Phase 2 Active not recruiting

Granulosa cell tumor of the ovary

NCT06979596 2026-04-13

OMAHA-015

Phase 2 Recruiting

Neoplasms

NCT07391774 2026-04-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Phase 3 Not yet recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT05467891 2026-04-08

RaPhLRR

Phase 2 Recruiting

Locoregional Recurrence

NCT04569747 2026-04-02

ADEPT

Phase 2 Active not recruiting

Breast Neoplasms

NCT05514054 2026-04-02

EMBER-4

Phase 3 Active not recruiting

Breast Neoplasms

NCT07499999 2026-03-30

BabyTEARS

Phase 2 Not yet recruiting

Breast Neoplasms, Carcinoma, Ductal

NCT05307705 2026-03-27

PIKASSO-01

Phase 1 Active not recruiting

Breast Neoplasms

NCT06492616 2026-03-27

ELEGANT

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT06428396 2026-03-24

LITESPARK-029

Phase 2 Recruiting

Breast Neoplasms

NCT05573126 2026-03-20

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT07174336 2026-03-20

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis